Ipilimumab + Nivolumab + VX15/2503
Phase 1ActiveDevelopment Stage
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Dec 13, 2018 → Dec 15, 2032
About Ipilimumab + Nivolumab + VX15/2503
Ipilimumab + Nivolumab + VX15/2503 is a phase 1 stage product being developed by Bristol Myers Squibb for Pathologic Stage IIIB Cutaneous Melanoma AJCC v8. The current trial status is active. This product is registered under clinical trial identifier NCT03769155. Target conditions include Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8.
What happened to similar drugs?
1 of 7 similar drugs in Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03769155 | Phase 1 | Active |
Competing Products
9 competing products in Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 40 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 40 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 44 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 32 |
| Gadoversetamide | Guerbet | Approved | 33 |
| α-lactalbumin vaccine + Zymosan | Anixa Biosciences | Phase 1 | 23 |